A combinatorial diagnostic protocol has the potential to offer a critical tool for accurate screening and identifying patients at the earliest stages of AD before the onset of irreversible injury and associated symptoms. CombiDiag aims to develop disease modifying interventions and anti-amyloid treatment within the health care systems. 

CombiDiag has the following scientific objectives(SOs), the accomplishment of which is crucial for the training through cutting edge research for our Fellows.

SO1.  To discover peripheral biomarkers from blood, saliva, urine, motor, speech and sleep by employing laboratory-based and cost-effective PoC techniques, clinical validations and statistical analysis.

SO2.  To cross-validate the above peripheral biomarkers on multimodal samples collected by a novel proof-of-concept clinical study.

SO3.  To develop an AI/data-driven combinatorial early AD diagnostic protocol based on peripheral AD markers in correlation with clinical gold standard.

SO4.  To create a CombiDiag data sharing platform that allows the public access of the datasets generated in our research

SO5.  To carry out clinical validation and trials for assessment of PoC biomarker detection techniques and the AI/data-driven combinatorial diagnostics.

SO6.  To develop an innovative business model and exploitation strategies for the AI/data-driven early-AD diagnostics and the PoC devices to maximise its societal and economic impact.

Research Fields

The consortium spans across the five major scientific disciplines Engineering, Physical Science, Life Science, Healthcare, and Economics. It entails highly interdisciplinary research. 

CombiDiag DN aims to develop an innovative researcher training methodology for the training of a new generation highly skilled Fellows for the AI/data-driven development of combinatorial peripheral biomarker based early-stage AD diagnostics at PoC settings. This will impact on the cost-effective diagnosis and case finding of early-stage AD patients for treatment as well as the development and delivery of new disease modifying drugs and preventive strategies, which are crucially important for meeting the medical and societal challenges imposed by AD as recognized in the Health, Demographic Change and Wellbeing of Horizon Europe, and the UN SDG.